AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 159 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $782,000 | -51.9% | 26,864 | -45.7% | 0.00% | -100.0% |
| Q4 2021 | $1,626,000 | -53.1% | 49,475 | -34.1% | 0.00% | -50.0% |
| Q3 2021 | $3,467,000 | -53.0% | 75,124 | -43.8% | 0.00% | -50.0% |
| Q2 2021 | $7,369,000 | +2.8% | 133,712 | -3.6% | 0.00% | 0.0% |
| Q1 2021 | $7,165,000 | +5.4% | 138,751 | -11.5% | 0.00% | 0.0% |
| Q4 2020 | $6,796,000 | +36.7% | 156,853 | +10.4% | 0.00% | 0.0% |
| Q3 2020 | $4,972,000 | -44.2% | 142,059 | -14.8% | 0.00% | -42.9% |
| Q2 2020 | $8,914,000 | +126.8% | 166,684 | +50.4% | 0.01% | +75.0% |
| Q1 2020 | $3,931,000 | -10.5% | 110,808 | +20.5% | 0.00% | +33.3% |
| Q4 2019 | $4,390,000 | +196.4% | 91,944 | +101.2% | 0.00% | +200.0% |
| Q3 2019 | $1,481,000 | -46.2% | 45,703 | -17.2% | 0.00% | -50.0% |
| Q2 2019 | $2,754,000 | -14.0% | 55,204 | +16.2% | 0.00% | -33.3% |
| Q1 2019 | $3,203,000 | +64.1% | 47,495 | +12.2% | 0.00% | +50.0% |
| Q4 2018 | $1,952,000 | -33.9% | 42,328 | +10.5% | 0.00% | -33.3% |
| Q3 2018 | $2,953,000 | -1.9% | 38,293 | +7.1% | 0.00% | 0.0% |
| Q2 2018 | $3,011,000 | +48.5% | 35,744 | +44.2% | 0.00% | +50.0% |
| Q1 2018 | $2,027,000 | +57.0% | 24,786 | +9.8% | 0.00% | +100.0% |
| Q4 2017 | $1,291,000 | -10.3% | 22,580 | +4.7% | 0.00% | -50.0% |
| Q3 2017 | $1,439,000 | +37.3% | 21,565 | +5.9% | 0.00% | +100.0% |
| Q2 2017 | $1,048,000 | -23.9% | 20,365 | -13.7% | 0.00% | -50.0% |
| Q1 2017 | $1,378,000 | +51.1% | 23,602 | +8.0% | 0.00% | +100.0% |
| Q4 2016 | $912,000 | -19.6% | 21,847 | +1.7% | 0.00% | -50.0% |
| Q3 2016 | $1,135,000 | +18.2% | 21,483 | -6.2% | 0.00% | 0.0% |
| Q2 2016 | $960,000 | +42.9% | 22,915 | +38.4% | 0.00% | +100.0% |
| Q1 2016 | $672,000 | +48.3% | 16,561 | +137.3% | 0.00% | 0.0% |
| Q4 2015 | $453,000 | -33.9% | 6,980 | -28.1% | 0.00% | 0.0% |
| Q3 2015 | $685,000 | +76.5% | 9,703 | +178.0% | 0.00% | 0.0% |
| Q2 2015 | $388,000 | +79.6% | 3,490 | +52.3% | 0.00% | – |
| Q1 2015 | $216,000 | – | 2,291 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |